Edinburgh Molecular Imaging

Edinburgh Molecular Imaging is a biopharmaceutical company developing molecular imaging and targeted therapeutic agents for cancer and other diseases.

Its research includes fluorescent peptide probes for image-guided surgery and radiolabelled compounds directed at c-Met, a receptor expressed in several tumour types. The company combines medicinal chemistry, imaging science and clinical development to support tumour visualisation and investigate targeted radiotherapy.

Its scientific programmes originate from University of Edinburgh research.